Review Decision - February 2016

Review of NICE Technology Appraisal Guidance No. 112; Hormonal therapies for the adjuvant treatment of early oestrogen-receptor-positive breast cancer

Decision to update the technology appraisal in an ongoing clinical guideline – February 2016

The Institute was proposing that TA112 should be updated in a forthcoming clinical guideline.

After consideration of all of the comments received during the Review Consultation, the Technology Appraisals programme has decided to proceed with this proposal.

Consequently, TA112 will be updated in the forthcoming update of CG80 (Early and locally advanced breast cancer: diagnosis and treatment), which is due to be published in July 2018. Upon publication of this clinical guideline, the recommendations in TA112 will be superseded, and the guidance will be withdrawn.

Appendix A - RPP decision paper - February 2016


This page was last updated: 22 February 2016